SEC Form 4 · accession 0001209191-18-061395
Acer Therapeutics Inc. · ACER
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Salma Jutt-Eghbali
Officer — Chief Commercial Officer
Period of report
Dec 4, 2018
Accepted (ET)
Dec 6, 2018 · 6:20 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001069308
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $22.18 | Dec 4, 2018 | A | 60,000 | A | — | Dec 4, 2028 | Common Stock | 60,000 | 60,000 | D |
Explanation of responses
- F1The option vests and becomes exercisable over four years as follows: 25% of the shares vest on December 4, 2019, and the remaining 75% vesting quarterly over the remaining three years.